Strategic divestiture TerSera is selling its Infusion Specialty Therapies Business Unit to Esteve Group, signaling a potential shift in portfolio focus and an opportunity to engage in new partnerships or to offer services around integration, divestiture support, or alternative therapy access programs.

Oncology focus With emphasis on oncology, acute care, and non-opioid pain management, there is a clear target for collaboration in hospital systems and specialty pharmacies seeking diversified non-opioid analgesics and oncology support products.

Strong workplace credibility Multiple 2024–2025 workplace accolades indicate a mature, people-centric culture, suggesting easier collaboration, smoother contracting, and stronger partner alignment with sales teams prioritizing reliability and customer-focused operations.

Moderate revenue base Revenue in the $100M–$250M range positions TerSera as a mid-market partner with appetite for scalable deals, co-development, or distribution arrangements that can leverage existing mid-size sales and payer negotiation capabilities.

Strategic partnerships history Past partnerships with AstraZeneca and TESARO for US/Canada rights imply a track record of external collaboration and potential interest in new licensing, distribution, or co-promotion deals to expand market presence.